| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 742.6MM | -0% |
| Gross Profit | 381.3MM | - |
| Cost Of Revenue | 361.3MM | -4% |
| Operating Income | 40.1MM | +52% |
| Operating Expenses | 341.2MM | - |
| Net Income | 7MM | -155% |
| R&D | 59.3MM | -5% |
| G&A | 187.6MM | -3% |
| Amortization | 51.2MM | -0% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
SAN DIEGO, April 17, 2024--QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today it will report its financial results for its first quarter ended March 31, 2024, after the market close on Wednesday, May 8, 2024.
SAN DIEGO, April 10, 2024--QuidelOrtho Corporation (Nasdaq: QDEL) has added the ARK™ Fentanyl II Assay to its U.S. Vitros® XT 7600 and 5600 Integrated Systems as well as its Vitros® 4600 Chemistry System menu of assays as a MicroTip® Partnership Assay ("MPA"). This Fentanyl assay will help hospital and emergency room customers respond to the critical demand for enhanced opioid testing, allowing on-site fentanyl testing in less than 10 minutes to aid in immediate clinical decisions.
Viewing insider transactions for QuidelOrtho Corporation's ( NASDAQ:QDEL ) over the last year, we see that insiders...
The diagnostics company said it is developing a next-generation combination respiratory assay after data for the initial test did not meet its expectations.
SAN DIEGO, April 02, 2024--QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho" or the "Company") has received U.S. Food and Drug Administration ("FDA") 510(k) clearance for its QuickVue COVID-19 test. This clearance allows the test to be used with accuracy and convenience in home and medical facility settings with CLIA certificates of waiver. This achievement also reflects QuidelOrtho’s dedication to delivering effective testing solutions while highlighting ongoing efforts in research and deve
Interim CEO Michael Iskra said in a recent presentation to investors the diagnostics firm plans to lay off less than 10% of its staff.
SAN DIEGO, March 06, 2024--QuidelOrtho Corporation (Nasdaq:QDEL) ("QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, has received approval from Health Canada for its Triage PLGF test for laboratory use in Canada. The Triage PLGF test is a fluorescence immunoassay to be used with the small footprint Triage MeterPro® Instrument for the quantitative determination of placental growth factor ("P
SAN DIEGO, February 26, 2024--QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced that members of its management team are scheduled to participate in the 45th Annual Raymond James Institutional Investor Conference on March 5, 2024, in Orlando, FL.
SAN DIEGO, February 21, 2024--The Board of Directors (the "Board") of QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho") has made significant decisions aimed to enhance operational efficiency, drive revenue growth and deliver shareholder value.
Bryant, who led the company since 2009, was fired after a challenging quarter and confusion over earnings forecasts.